Valvular & structural heart diseaseCohort study
Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry
- Multicentre registry study
- consecutive patients
- 11 US centres
Authors' conclusion
In this large multicenter real-world experience, short-term clinical and hemodynamic outcomes of self-expanding TPVR therapy were excellent.
Study context
- Population
- Patients with native right ventricular outflow tract (RVOT) pulmonary regurgitation undergoing transcatheter pulmonary valve replacement (TPVR) through April 30, 2022
- Participants
- 243 patients
- Outcome
- Composite of:
- Hemodynamic dysfunction (pulmonary regurgitation (PR) greater than mild and RVOT mean gradient >30 mm Hg)
- RVOT reintervention
Main finding
As reported in the abstract
Freedom from composite of:
- Hemodynamic dysfunction
- RVOT reintervention (estimated)
Freedom from composite outcome at 1 year
99%
Freedom from composite outcome at 2 years
96%
Observational data: associations, not effects.
Further findings
Acceptable hemodynamic function · median follow-up 13 months (Q1-Q3: 8-19 months)
- Patients with acceptable hemodynamic function
- 98%
Acute technical success
- Achieved in all but 1 case
Hospital length of stay
- Length of stay 1 day
- 86%
Freedom from TPVR-related endocarditis · 1 year
- Freedom from TPVR-related endocarditis at 1 year
- 98%
Deaths
- Deaths
- 5
- COVID-19
- 1
- Unknown causes
- 2
- Bloodstream infection
- 2
Safety
Procedural serious adverse events
- Procedural serious adverse events
- 4%
- Device embolization or death
- 0
Ventricular arrhythmia prompting treatment
- Ventricular arrhythmia prompting treatment
- 19%
Original publication
Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry. J Am Coll Cardiol. Published 9 April 2024. doi:10.1016/j.jacc.2024.02.010
Summarised from the published abstract; every number is checked against it